Study 8 of 36Abaloparatide (Tymlos) literatureNatureTop journal2026
De novo design of miniproteins targeting GPCRs.
Not reported in abstract.
Where it sits
this study against the rest of the abaloparatide (tymlos) corpus9
Preclinical · this one
12
Observational
0
Open-label
3
Randomised
12
Reviews
Summary and findings
Not reported in abstract.
How much of this paper we could read: title only (0.10). The feed gave us little more than the title, so our summary is thin. This says nothing about the study's quality — read the source. What this means →
2026
Background
Not reported in abstract.
Methods
Not reported in abstract.
Results
Not reported in abstract.
Interpretation
Not reported in abstract.
Limitations
Not reported in abstract.
Elsewhere in the Abaloparatide (Tymlos) corpus
CBone anabolic agents repair alveolar bone damaged by diabetes in mice.International journal of oral science · 2026 · Not reported in abstract.AnimalABeyond antifracture efficacy: Osteoanabolic versus antiresorptive therapy for chronic pain after osteoporotic vertebral fractures. A systematic review and meta-analysis.Bone · 2026 · n=4029 · Not reported in abstract.reviewABone Anabolic Treatment in Patients With Chronic Kidney Disease: A Systematic Review.Basic & clinical pharmacology & toxicology · 2023 · n=66 · Not reported in abstract.reviewBReal-world comparison of abaloparatide and romosozumab: effects on bone mineral density and three-dimensional hip structure.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2023 · n=102 · Significant increases in lumbar spine BMD at 12 months, P<0.001.HumanDAnti-osteoporotic Pharmacotherapy and Muscle Outcomes in Osteosarcopenia: a Source-Verified Translational Evidence Map.Calcified tissue international · 2026 · Not reported in abstract.reviewDCardiovascular Safety Signals of Osteoporosis Therapies: A FAERS Pharmacovigilance Study.Mediterranean journal of rheumatology · 2026 · Romosozumab demonstrated the highest ROR for MI (2.38) and stroke (3.72).review